Literature DB >> 1442327

Use of the rat air pouch model of inflammation to evaluate regional drug delivery.

D E Davies1, A J Stevens, J B Houston.   

Abstract

We have used the rat inflammatory air pouch model to investigate some of the pharmacokinetic and pharmacodynamic issues relating to regional drug delivery. S(+)Ibuprofen was administered either intravenously or directly into the air pouch at the same time as the irritant (carrageenan). Serial samples of exudate and plasma were then taken and assayed for drug concentrations and various efficacy markers. Ibuprofen given intrapouch, was found to inhibit in a dose-dependent manner the concentration of prostaglandin E2 and the number of white cells in the exudate. Plasma and pouch concentration-time profiles are described for s(+)Ibuprofen: there is evidence for greater drug retention in the pouch than in plasma following regional and systemic delivery.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1442327

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  4 in total

1.  C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes.

Authors:  Uma Singh; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Clin Chem       Date:  2008-12-12       Impact factor: 8.327

2.  C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo.

Authors:  Sridevi Devaraj; Mohan R Dasu; Uma Singh; L Vijaya Mohan Rao; Ishwarlal Jialal
Journal:  Atherosclerosis       Date:  2008-06-13       Impact factor: 5.162

3.  Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.

Authors:  U Singh; M R Dasu; P G Yancey; A Afify; S Devaraj; I Jialal
Journal:  J Lipid Res       Date:  2008-02-02       Impact factor: 5.922

4.  Prostaglandin E2 induces upregulation of Na+ transport across Xenopus lung epithelium.

Authors:  A Berk; M Fronius; W Clauss; M Schnizler
Journal:  J Comp Physiol B       Date:  2003-10-29       Impact factor: 2.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.